• Home
  • Search Results
  • Prevention of bleomycin-induced lung inflammation and fibrosis in mice by naproxen and JNJ7777120 treatment.

Prevention of bleomycin-induced lung inflammation and fibrosis in mice by naproxen and JNJ7777120 treatment.

The Journal of pharmacology and experimental therapeutics (2014-09-04)
Arianna Carolina Rosa, Alessandro Pini, Laura Lucarini, Cecilia Lanzi, Eleonora Veglia, Robin L Thurmond, Holger Stark, Emanuela Masini
ABSTRACT

Pulmonary fibrosis, a progressive and lethal lung disease characterized by inflammation and accumulation of extracellular matrix components, is a major therapeutic challenge for which new therapeutic strategies are warranted. Cyclooxygenase (COX) inhibitors have been previously utilized to reduce inflammation. Histamine H4 receptor (H4R), largely expressed in hematopoietic cells, has been identified as a novel target for inflammatory and immune disorders. The aim of this study was to evaluate the effect of JNJ7777120 (1-[(5-chloro-1H-indol-2-yl)carbonyl]-4-methylpiperazine), a selective H4R antagonist, and naproxen, a well known nonsteroidal anti-inflammatory drug, and their combination in a murine model of bleomycin-induced fibrosis. Bleomycin (0.05 IU) was instilled intratracheally to C57BL/6 mice, which were then treated by micro-osmotic pump with vehicle, JNJ7777120 (40 mg/kg b.wt.), naproxen (21 mg/kg b.wt.), or a combination of both. Airway resistance to inflation, an index of lung stiffness, was assessed, and lung specimens were processed for inflammation, oxidative stress, and fibrosis markers. Both drugs alone were able to reduce the airway resistance to inflation induced by bleomycin and the inflammatory response by decreasing COX-2 and myeloperoxidase expression and activity and thiobarbituric acid-reactive substance and 8-hydroxy-2'-deoxyguanosine production. Lung fibrosis was inhibited, as demonstrated by the reduction of tissue levels of transforming growth factor-β, collagen deposition, relative goblet cell number, and smooth muscle layer thickness. Our results demonstrate that both JNJ7777120 and naproxen exert an anti-inflammatory and antifibrotic effect that is increased by their combination, which could be an effective therapeutic strategy in the treatment of pulmonary fibrosis.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Collagen, Type I solution from rat tail, BioReagent, suitable for cell culture, sterile-filtered
Sigma-Aldrich
Collagen from human placenta, Bornstein and Traub Type IV, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Collagen from rat tail, Bornstein and Traub Type I, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Collagen from human placenta, Bornstein and Traub Type IV, powder
Sigma-Aldrich
Collagen from calf skin, Bornstein and Traub Type I, (0.1% solution in 0.1 M acetic acid), aseptically processed, BioReagent, suitable for cell culture
Sigma-Aldrich
Bleomycin sulfate from Streptomyces verticillus, 1.5-2.0 units/mg solid, BioReagent, suitable for cell culture
Sigma-Aldrich
Collagen from bovine achilles tendon, powder, suitable for substrate for collagenase
Sigma-Aldrich
Collagen from chicken sternal cartilage, Type II (Miller), powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Collagen from calf skin, Bornstein and Traub Type I, solid, BioReagent, suitable for cell culture
Sigma-Aldrich
Collagen Type IV from human cell culture, Bornstein and Traub Type IV, 0.3 mg/mL, sterile-filtered, BioReagent, suitable for cell culture
Supelco
Naproxen, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
8-Hydroxy-2′-deoxyguanosine, ≥98% (TLC)
Sigma-Aldrich
Argon, ≥99.998%
Sigma-Aldrich
Bleomycin sulfate from Streptomyces verticillus, crystalline, 1.5-2.0 U/mg
Sigma-Aldrich
Naproxen, meets USP testing specifications
Bleomycin sulfate, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Collagen from human placenta, Bornstein and Traub Type I (Sigma Type VIII), powder
Sigma-Aldrich
Bleomycin sulfate from Streptomyces verticillus, BioXtra, crystalline
Sigma-Aldrich
(S)-(+)-6-Methoxy-α-methyl-2-naphthaleneacetic acid, 98%
Sigma-Aldrich
Collagen from calf skin, Bornstein and Traub Type I (Sigma Type III), solid
Sigma-Aldrich
Collagen from bovine nasal septum, Bornstein and Traub Type II, powder
Sigma-Aldrich
Collagen human, Bornstein and Traub Type I, acid soluble, powder, ~95% (SDS-PAGE)
Sigma-Aldrich
Collagen from human placenta, Bornstein and Traub Type III (Sigma Type X), powder
Sigma-Aldrich
Collagen from Engelbreth-Holm-Swarm murine sarcoma basement membrane, Type IV (Miller), lyophilized powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Bleomycin sulfate from Streptomyces verticillus, for fluorescence, mixture of bleomycin sulfate salts, lyophilized, powder or crystals, white to off-white
Supelco
Naproxen, VETRANAL®, analytical standard
Sigma-Aldrich
Collagen from human placenta, Bornstein and Traub Type IV, solution, suitable for cell culture, High Performance
Sigma-Aldrich
Collagen from rat tail, Bornstein and Traub Type I (Sigma Type VII), powder
USP
Naproxen, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Collagen from bovine tracheal cartilage, Bornstein and Traub Type II, powder

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.